Literature DB >> 472894

Paget's disease. Reversal of severe paraparesis using calcitonin.

L A Walpin, F R Singer.   

Abstract

Relatively short-term treatment of paraparesis due to Paget's disease with subcutaneous salmon calcitonin alone produced dramatic relief of sensory loss, pain, and paraparesis. The successful outcomes in 2 patients, one with spinal cord and one with cauda equina compression, indicate a potential alternative to surgery in reversing mild-to-severe neural dysfunction in Pagets disease. The proposed mechanisms of action of calcitonin include reduction of a direct bony impingement on the neural tissue and/or a decrease of neural ischemia. It is suggested that even if paraparesis does not improve with calcitonin alone, the medication given preoperatively would probably serve a useful adjunctive role by decreasing intraoperative bone bleeding. However, those patients whose pagetic bone is already metabolically inactive would probably not benefit from calcitonin therapy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 472894

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  2 in total

1.  Randomised placebo-controlled trial on the effectiveness of nasal salmon calcitonin in the treatment of lumbar spinal stenosis.

Authors:  Suhayl I Tafazal; Leslie Ng; Philip Sell
Journal:  Eur Spine J       Date:  2006-07-25       Impact factor: 3.134

Review 2.  Management of Paget's disease of bone.

Authors:  I R Reid
Journal:  Osteoporos Int       Date:  2019-12-17       Impact factor: 4.507

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.